Wire · opportunities
Taiho scores phase 3 win with oral cancer combo for AML-causing blood disorders
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
Taiho Pharmaceuticals reported positive phase 3 trial results for an all-oral combination of azacitidine and cedazuridine treating myelodysplastic syndromes and chronic myelomonocytic leukemia, which can lead to acute myeloid leukemia. The company plans to submit a new drug application to the FDA based on these results.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Oral chemotherapy options are becoming standard for complex blood cancers, creating a race to convert injectable treatments into pills. Your biotech startup must rethink clinical strategies around oral delivery to compete with this shift.
◆ Coverage
1 source · 1 Oct 2026
◆ Related on Wire
◆ Topics